Author: admin

48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα Data from multiple combination studies sponsored by the Company and its partner continue to support

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: